Can Patent Duration Hinder Medical Innovation for Neglected Diseases?

Leoni, Patrick L.; Sandroni, Alvaro

doi:10.2139/ssrn.1950700

Cited by 1 publication

(1 citation statement)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Considering the current challenges for the availability and accessibility of drugs for neglected diseases, several authors and organisations have called into question the relevance of patents in the TRIPS Agreement on pharmaceutical R&D and global health (Hubbard & Love, , pp. 0147–0148; Leoni & Sandroni, , pp. 2–18; Malpani et al, , p. 1; Oguamanam, , pp.…”

Section: Part Ii: Patents the Trips Agreement And Access To Essentimentioning

confidence: 99%

A re‐evaluation of the framework for the protection of patents, women’s health in Nigeria and the issue of accessing pharmaceutical innovation in Africa: Designing strategies for medicines

Mike

2019

World Intellectual Property

View full text Add to dashboard Cite

The objective of this study is to make a case for Nigerian women to have access essential medicines in light of patent protection of pharmaceuticals. Consequently, this study argues for an improvement of women's access to medicines within the context of patent law and rights, the available flexibilities in the international IP regime of the Trade Related Aspect of Intellectual Property Rights (TRIPS) Agreement and Nigeria's national patent system. Towards this goal, the article makes the point that patent law and its exclusive rights, both the TRIPS Agreement and national law of Nigeria, do not exist in a social welfare vacuum. The legal text of patent law, which confers rights on inventors when enforced, translates to many other things outside the sphere of property rights; indeed, it can be a matter of life and death. It is argued in this regard that patent right could, in effect, interfere with access to medicines and therefore, the right to health and prospects for human development. This study adopts a doctrinal methodology to examine, analyse, and evaluate the issues that have arisen in the context of patent protection of pharmaceuticals and its effect on access medicines. It concludes that while the hindrances to accessibility of essential drugs in Nigeria are multifaceted and demand a multidimensional approach for a lasting solution, the TRIPS flexibilities are significant means for addressing the challenges of affordable access to important health treatments within the context of patent law. However, it is emphasised that utilising the flexibilities will require that Nigeria's patent system is strategically designed to take full advantage of the available exceptions, safeguards, and options.

show abstract

Section: Part Ii: Patents the Trips Agreement And Access To Essentimentioning

confidence: 99%

A re‐evaluation of the framework for the protection of patents, women’s health in Nigeria and the issue of accessing pharmaceutical innovation in Africa: Designing strategies for medicines

Mike

2019

World Intellectual Property

View full text Add to dashboard Cite

show abstract

Can Patent Duration Hinder Medical Innovation for Neglected Diseases?

Cited by 1 publication

References 18 publications

A re‐evaluation of the framework for the protection of patents, women’s health in Nigeria and the issue of accessing pharmaceutical innovation in Africa: Designing strategies for medicines

A re‐evaluation of the framework for the protection of patents, women’s health in Nigeria and the issue of accessing pharmaceutical innovation in Africa: Designing strategies for medicines

Contact Info

Product

Resources

About